ReviewBio-design and manufacturing2021
Application of lung microphysiological systems to COVID-19 modeling and drug discovery: a review.
Review in Bio-design and manufacturing, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Microfluidic lung-on-a-chip for evaluating inflammation and toxicity from environmental pollutants.Frontiers in bioengineering and biotechnology · 2026Review
- Modeling of lung-liver interaction during infection in a human fluidic organ-on-a-chip.Scientific reports · 2025Article
- Organ-on-a-Chip Applications in Microfluidic Platforms.Micromachines · 2025Review
- Microphysiological systems to advance human pathophysiology and translational medicine.Journal of applied physiology (Bethesda, Md. : 1985) · 2024Review
- Microfluidic strategies for biomimetic lung chip establishment and SARS-CoV2 study.Materials today. Bio · 2024Review
- Organ-on-chip technology: Opportunities and challenges.Biotechnology notes (Amsterdam, Netherlands) · 2024Review
- Cytokine production in anFrontiers in immunology · 2024Article
- Simple design for membrane-free microphysiological systems to model the blood-tissue barriers.Organs-on-a-chip · 2023Article
- Simple Design for Membrane-Free Microphysiological Systems to Model the Blood-Tissue Barriers.bioRxiv : the preprint server for biology · 2023Article
- Disruptive 3D in vitro models for respiratory disease investigation: A state-of-the-art approach focused on SARS-CoV-2 infection.Biomaterials and biosystems · 2023Article
- In vitro high-content tissue models to address precision medicine challenges.Molecular aspects of medicine · 2023Review
- Autophagy and SARS-CoV-2-Old Players in New Games.International journal of molecular sciences · 2023Review
- The Synergy between Deep Learning and Organs-on-Chips for High-Throughput Drug Screening: A Review.Biosensors · 2023Review
- Microfluidic-based technologies for diagnosis, prevention, and treatment of COVID-19: recent advances and future directions.Biomedical microdevices · 2023Review
- Engineering organ-on-a-chip systems to model viral infections.Biofabrication · 2023Review
- Biomimetic lung-on-a-chip to model virus infection and drug evaluation.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2023Review
- Advanced Microfluidic Vascularized Tissues as Platform for the Study of Human Diseases and Drug Development.Current neuropharmacology · 2023Article
- Post-COVID Syndrome: The Research Progress in the Treatment of PulmonaryPharmaceutics · 2022Review
- Development and evaluation of a bovine lung-on-chip (bLOC) to study bovine respiratory diseases.In vitro models · 2022Article
- Engineering viral genomics and nano-liposomes in microfluidic platforms for patient-specific analysis of SARS-CoV-2 variants.Theranostics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
There is a pressing need for effective therapeutics for coronavirus disease 2019 (COVID-19), the respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. The process of drug development is a costly and meticulously paced process, where progress is often hindered by the failure of initially promising leads. To aid this challenge, in vitro human microphysiological systems need to be refined and adapted for mechanistic studies and drug screening, thereby saving valuable time and resources during a pandemic crisis. The SARS-CoV-2 virus attacks the lung, an organ where the unique three-dimensional (3D) structure of its functional units is critical for proper respiratory function. The in vitro lung models essentially recapitulate the distinct tissue structure and the dynamic mechanical and biological interactions between different cell types. Current model systems include Transwell, organoid and organ-on-a-chip or microphysiological systems (MPSs). We review models that have direct relevance toward modeling the pathology of COVID-19, including the processes of inflammation, edema, coagulation, as well as lung immune function. We also consider the practical issues that may influence the design and fabrication of MPS. The role of lung MPS is addressed in the context of multi-organ models, and it is discussed how high-throughput screening and artificial intelligence can be integrated with lung MPS to accelerate drug development for COVID-19 and other infectious diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.